Am J Ther [JOURNAL]

BACKGROUND: Hospital-based analyses of real-world percutaneous coronary intervention (PCI) practice remain limited. STUDY QUESTION: How do PCI strategies in non-ST-elevation acute coronary syndromes (ACSs) compare betwee... BACKGROUND: Hospital-based analyses of real-world percutaneous coronary intervention (PCI) practice remain limited. STUDY QUESTION: How do PCI strategies in non-ST-elevation acute coronary syndromes (ACSs) compare between 2 university hospitals from European countries with different cardiovascular disease burdens, health care systems, and interventional cardiology infrastructures [University and Emergency Hospital, Bucharest, Romania (RO) and University Hospital, Essen, Germany (GER)]? STUDY TYPE: Retrospective, observational, all-comers. MEASURES AND OUTCOMES: All consecutive high- and very high-risk patients with non-ST-elevation ACS undergoing PCI in 2022 were analyzed regarding clinical profiles and revascularization strategies. METHODS AND RESULTS: A total of 392 patients were included (221 RO, 171 GER). RO patients had a worse cardiovascular risk profile, with higher rates of dyslipidemia, diabetes, prior ACS, and left ventricular ejection fraction (LVEF) ≤40% (all P < 0.05). P2Y12 inhibitor pretreatment was markedly higher in RO (78.3% vs. 1.3%, P < 0.001). Despite younger age in RO (64.3 vs. 71.8 years, P < 0.001), median SYNTAX scores (12 vs. 13), left main disease (10.9% vs. 11.1%), and multivessel disease (64.3% vs. 62.6%) were comparable. Radial access (80.5% RO vs. 73.1% GER), ad hoc culprit PCI (98.6% RO vs. 93.0% GER), and complete anatomical revascularization (residual SYNTAX score ≤8; 83.3% RO vs. 77.2% GER) represented standard practice in both hospitals. Use of adjunctive PCI techniques was higher in GER, with intravascular imaging-guided PCI reported only in the German hospital (29.8% of PCIs). In-hospital major adverse cardiac and cerebrovascular events were comparable (10.4% RO vs. 7.6% GER, P > 0.05) and consistently associated with lower LVEF ( P < 0.001). CONCLUSIONS: Compared with the German cohort, the Romanian cohort had a similar coronary artery disease burden but a worse overall cardiovascular risk profile at a younger age. Arterial access, PCI timing, and revascularization completeness were similar, while adjunctive PCI techniques were used more frequently in GER. In-hospital major adverse cardiac and cerebrovascular events rates were comparable and consistently associated with lower LVEF.

Get PDF PubMed ↗

Letter to the Editor: Methodological Concerns in Bryant et al.'s Network Meta-Analysis on Residual Disease Thresholds in Advanced Ovarian Cancer.

Saim M

Am J Ther · 2026 May-Jun 01 · PMID 41952063 · Publisher ↗

Abstract loading — click title to view on PubMed.

Get PDF PubMed ↗

Opioid Withdrawal Precipitated by Buprenorphine-Naloxone Combination in a Patient With Methadone Maintenance Therapy.

Chen YC, Chen TY, Wang SH … +4 more , Li ST, Yao CY, Cheng C, Tzeng NS

Am J Ther · 2026 May-Jun 01 · PMID 41952055 · Publisher ↗

Abstract loading — click title to view on PubMed.

Get PDF PubMed ↗

Meta-Analysis Evaluating the Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Heart Failure Stratified by Frailty Index.

Siddiqui HF, Siddiqui AF, Batool RM … +9 more , Saadia S, Ayub MZ, Asim H, Khan MA, Ramani AK, Ahmad M, Ahmed A, Mukaty HH, Siddiqui AF

Am J Ther · 2026 Apr · PMID 41917723 · Publisher ↗

Abstract loading — click title to view on PubMed.

Get PDF PubMed ↗

Tislelizumab-Associated Bullous Pemphigoid.

Lei Y, Gan YT, Qiu ZJ … +4 more , Cheng JR, Liu XY, Liu JJ, Shi BJ

Am J Ther · 2026 May-Jun 01 · PMID 41870227 · Publisher ↗

Abstract loading — click title to view on PubMed.

Get PDF PubMed ↗

Safety and Efficacy of Blinatumomab Versus Chemotherapy for Acute Lymphoblastic Leukemia: A Meta-analysis Involving 2177 Patients.

Cheema S, Ijaz H, Rafay-Ur-Rehman M … +9 more , Cheema U, Masood S, Seerat Ali M, Faique Hassan M, Fatima F, Aslam F, Faheem MSB, Mohammed YN, Lal A

Am J Ther · 2026 Mar · PMID 41844553 · Publisher ↗

Abstract loading — click title to view on PubMed.

Get PDF PubMed ↗

Donepezil for Korsakoff Syndrome.

Fallone M, Sivananthan M, Joseph M

Am J Ther · 2026 May-Jun 01 · PMID 41839797 · Publisher ↗

BACKGROUND: Korsakoff syndrome is a neurocognitive disorder characterized by memory impairment and confabulation caused by severe or prolonged thiamine deficiency. It is preceded by a type of delirium called Wernickes En... BACKGROUND: Korsakoff syndrome is a neurocognitive disorder characterized by memory impairment and confabulation caused by severe or prolonged thiamine deficiency. It is preceded by a type of delirium called Wernickes Encephalopathy, which is reversible. However, once a patient progresses to Korsakoff syndrome, treatment options are limited because there are currently no FDA-approved medications for Korsakoff syndrome. Donepezil is an acetylcholinesterase inhibitor that has shown efficacy in Alzheimer disease and has been theorized to have benefit in other neurologic disorders as well. In this case, we present a patient with Korsakoff syndrome who had improvement in symptoms after starting donepezil. DATA SOURCE: The information presented here is derived directly from the clinical records and observations of the patient under our care. FINDINGS AND LIMITATIONS: The case presented here demonstrates improvement in cognition, motivation, and affect in Korsakoff dementia with the use of donepezil. Limitations of this case study and those alike include lack of generalizability, retrospective design, and absence of a control. CONCLUSIONS: The off-label use of donepezil for Korsakoff syndrome in this case and others has been shown to be beneficial and well tolerated. Ultimately, larger studies are needed to determine safety and efficacy.

Get PDF PubMed ↗